Oncocyte to Announce First Quarter 2022 Financial Results
April 28 2022 - 4:01PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company with the mission to improve patient outcomes by providing
personalized insights that inform critical decisions throughout the
patient care journey, announced today that it will release its
first quarter 2022 financial results on Wednesday, May 11, 2022. In
conjunction with the release, Oncocyte will host a conference call
and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern
Time to discuss its financial results and recent highlights.
Interested parties may access the live call via
telephone by dialing (877) 407-9716 for domestic callers or (201)
493-6779 for international callers, using conference ID: 13729461.
The live webinar of the call may be accessed by visiting the
“Events & Presentation” section of the Company’s website at
https://investors.oncocyte.com. A replay of the webinar will be
available on the Company’s website shortly after the conclusion of
the call.
About OncocyteOncocyte is a
precision diagnostics and monitoring company with the mission to
improve patient outcomes by providing clear insights that inform
critical decisions in the diagnosis, treatment, and monitoring of
cancer. The Company, through its proprietary tests and
pharmaceutical services business, aims to help save lives by
accelerating the diagnosis of cancer and advancing cancer care. The
Company’s tests are designed to help provide clarity and confidence
to physicians and their patients at every stage post-diagnosis
treatment. DetermaRx™ identifies early-stage lung cancer patients
who are at high risk for cancer recurrence and who may benefit from
adjuvant chemotherapy. DetermaIO™, a gene expression test currently
used as a research-use only tool, assesses the tumor
microenvironment to predict response to immunotherapies. The
Company’s pipeline of tests in development also includes
DetermaTx™, which will assess mutational status of a tumor,
blood-based test DetermaCNI™, which can monitor cancer patients for
recurrence of disease, long-term recurrence monitoring test
DetermaMx™, and blood-based solid organ transplantation monitoring
test TheraSure™. In addition, Oncocyte’s pharmaceutical services
provide companies that are developing new cancer treatments a full
suite of molecular testing services to support the drug development
process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and
TheraSure™ are trademarks of Oncocyte Corporation.
Investor ContactCaroline CornerICR
Westwicke(415) 202-5678caroline.corner@westwicke.com
Media ContactMegan KernanICR Westwicke
Healthcare PRTel: 646.677.1870Megan.kernan@westwicke.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Sep 2023 to Sep 2024